Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells<i>in vitro</i>and<i>in vivo</i>

Wang, Fusheng; Liu, Mingxu; Zhang, Bing; Shi, Ming; Lei, Zhou-Yun; Sun, Wen‐Hua; Du, Qingyou; Chen, Jumei

doi:10.3748/wjg.v8.i3.464

Cited by 97 publications

(78 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD3 + CD56 + cells are able to expand nearly 1 000-fold when they are cultured with a cytokine cocktail comprising interferon-γ (IFN-γ), interleukin-2 (IL-2), mAbs against CD3, and interleukin-1α (IL-1α), and have a characteristic which is more effective in the treatment of tumors with a non-major histocompatibility complex (MHC)-restricted mechanism, and a most effective project [6] . We have previously reported that CIK cells could suppress the growth of tumor cells in vitro when HCC cells were transplanted in mice [7][8][9][10] . Dendritic cells (DCs) are specialized antigen-presenting cells (APC) in the immune system.…”

Section: Introductionmentioning

confidence: 99%

Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma

Shi¹,

Zhang²,

Tang³

et al. 2004

WJG

Self Cite

117

View full text Add to dashboard Cite

AIM:To investigate the influence of autologous cytokineinduced killer (CIK) cells on the phenotypes of CIK effector cells, peripheral T lymphocyte subsets and dendritic cell subsets in patients with primary hepatocellular carcinoma (HCC). METHODS: Peripheral blood mononuclear cells (PBMC)were collected by a blood cell separator from 13 patients with HCC, then expanded by priming them with interferongamma (IFN-γ) followed by monoclonal antibody (mAb) against CD3 and interleukin-2 (IL-2) the next day. The phenotypic patterns of CIK cells were characterized by flow cytometry on d 0, 4, 7, 10, 13 and 15 of incubation, respectively. Then, 5 mL of venous blood was obtained from HCC patients before or 8-10 d after CIK cells were transfused into patients to assess the influence of CIK cells on the percentages of effector cells, and proportions of DC1 or DC2 in peripheral blood by flow cytometry. + cells began to decrease on d 7 and 13, respectively. The proportions of type I dendritic cell (DC1) and type II dendritic cell (DC2) subsets increased from 0.59±0.23% and 0.26±0.12% before CIK cell therapy to 0.85±0. 27% and 0.43±0.19% (all P<0.01) after CIK cell transfusion, respectively. The symptoms and characteristics of HCC patients were relieved without major side effects. RESULTS: CONCLUSION:Our results indicated that autologous CIK cells can efficiently improve the immunological status in HCC patients, and may provide a potent approach for HCC patients as the adoptive immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma

Shi¹,

Zhang²,

Tang³

et al. 2004

WJG

Self Cite

117

View full text Add to dashboard Cite

show abstract

“…A suitable method for evaluation of the immunoenhancing effects of immunotherapy has not been established yet. In humans, most of the cells obtained by cultivation of activated lymphocytes are reported to be cluster of differentiation (CD)-3 + T or NK cells [17], and the cytotoxic activity of these cells has been proved to increase after cultivation [40]. When canine lymphocytes were cultured with anti-CD3 antibody and human recombinant (hr) interleukin (IL)-2, the number of lymphocytes was observed to have increased [24].…”

mentioning

confidence: 99%

Phenotypic Analysis and Effects of Sequential Administration of Activated Canine Lymphocytes on Healthy Beagles

Hoshino

Takagi

Osaki

et al. 2008

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. We attempted to accumulate the basic data for evaluation of activated lymphocyte therapy for small animal medicine. The peripheral blood mononuclear cells (PBMCs) collected from healthy dogs were activated using anti-CD3 antibody and human recombinant (hr) interleukin (IL)-2 and reactivated using hr interferon (IFN)-α and hr IL-2. The property of obtained cells was compared with PBMCs. The number of cells was shown to have increased approximately > 50 -fold by cultivation. The proportion of CD8 + cells was significantly increased, the cytotoxicity of the cultured cells was revealed to have been reinforced. Additionally, CD56 mRNA levels tended to have increased. The cells obtained by this method were confirmed to be activated lymphocytes. Furthermore, we investigated the effects of sequential administration of the obtained cells to healthy dogs. By sequential administration of the activated lymphocytes, the cell proliferative activity, proportion of CD4 + cells and CD8 + cells, and serum IFN-γ concentration were shown to have increased, and no severe adverse effects were observed. Consequently, activated lymphocytes could be induced using anti-CD3 antibody and IL-2 in healthy dogs, and sequential administration of activated lymphocytes reinforced the recipient's immunity.

show abstract

“…In 1991, Schmidt-Wolf et al (11) first reported that CIK cells possessed potential antitumor cell activity in the immunodeficient SCID mouse/human lymphoma model. Following this finding, additional studies indicated that CIK cells may be a better choice for patients with solid tumors and demonstrated that CIKs possess strong antitumor activity in vitro (24)(25)(26). A number of previous studies have also demonstrated that CIKs may reverse drug resistance in solid tumor cells (24)(25)(26).…”

Section: Discussionmentioning

confidence: 84%

Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review

2015

View full text Add to dashboard Cite

Abstract. Metastatic malignant melanoma is treated with chemotherapy and radiotherapy. A number of previous studies have indicated that cytokine-induced killer cells (CIK cells) are a heterogeneous cell population that express cluster of differentiation (CD)3 and CD56, in addition to the natural killer cell NKG2D activating receptor. CIK cells possess major histocompatibility complex-unrestricted cytotoxicity towards cancer, but not towards normal targets. The present study investigated whether the addition of CIK cells resulted in an improved therapeutic response in a patient with metastatic malignant melanoma. In the current case, a patient with metastatic malignant melanoma received CIK therapy, which resulted in a relatively long survival time of 28 months. To the best of our knowledge, there have been no previous studies reporting such positive effects in a patient who received CIK cell immunotherapy. Based on the findings of the present study, CIK cell therapy may be an option that results in a good prognosis in certain patients with metastatic malignant melanoma.

show abstract

Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cellsin vitroandin vivo

Abstract: Autologous CIK cells are of highly efficient cytotoxic effector cells against primary hepatocellular carcinoma cells and might serve as an alternative adoptive therapeutic strategy for HCC patients.

Cited by 97 publications

References 27 publications

Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma

Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma

Phenotypic Analysis and Effects of Sequential Administration of Activated Canine Lymphocytes on Healthy Beagles

Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review

Contact Info

Product

Resources

About